PDF(Pubmed)
Abstract：
Some cases of bronchial asthma are refractory to conventional therapies. As the pathogenesis of bronchial asthma has been clarified, new treatments, such as bronchial thermoplasty and biological drugs, have been developed. Tezepelumab, an anti-thymic stromal lymphopoietin antibody, has been reported to inhibit the exacerbation of severe asthma; however, its adverse effects on glucose metabolism have not yet been reported. We encountered a case of weight gain and worsening glycemic management in a patient with type 2 diabetes and refractory bronchial asthma after the initiation of tezepelumab treatment. It has been reported that the overexpression of thymic stromal lymphopoietin in mice resulted in an enhanced release of free fatty acids from adipose tissues and the liver; thus, the administration of anti-thymic stromal lymphopoietin antibodies in the present case might have caused obesity, fatty liver and lower glucose tolerance.
摘要：
一些支气管哮喘病例对常规治疗难以治疗。随着支气管哮喘发病机制的阐明,新的治疗方法,如支气管热成形术和生物药物，已经开发了。Tezepelumab,抗胸腺基质淋巴细胞生成素抗体，据报道可以抑制严重哮喘的恶化；然而，其对糖代谢的不利影响尚未有报道.我们遇到一例2型糖尿病和难治性支气管哮喘患者在开始使用tezepelumab治疗后体重增加和血糖管理恶化的病例。据报道，小鼠胸腺基质淋巴细胞生成素的过表达导致脂肪组织和肝脏中游离脂肪酸的释放增加；因此，在本病例中施用抗胸腺基质淋巴细胞生成素抗体可能导致肥胖，脂肪肝和低糖耐量。
